Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers.

The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).

[1] It uses a more hindered disulfide linkage than cantuzumab mertansine.

[2] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.